Safety and Efficacy of a Single Dose of a Polyphenol-enriched Brown Seaweed Powder in Human
Phase 1
Completed
- Conditions
- Glycemic Index
- Registration Number
- NCT00936754
- Lead Sponsor
- innoVactiv Inc.
- Brief Summary
The primary endpoint of this trial will be to evaluate the safety of a single administration in human of a dose of 500 mg of a polyphenol-rich algal powder when taken 30 minutes before a test meal. The secondary endpoint of this trial will be to evaluate if a single administration in human of a dose of 500 mg of a polyphenol-rich algal powder is able to reduce the rate of carbohydrate absorption as measured by following postprandial glycemia and insulinemia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
- Healthy volunteer
- BMI between 20 and 30
- Non-smoking
Exclusion Criteria
- Iodine allergy
- Diabetes
- Use of dietary supplements for duration of study
- History of major surgeries or surgeries of the stomach or digestive tract
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Safety of a single 500 mg administration of a brown seaweed extract in human First administration up to 7 days after last administration
- Secondary Outcome Measures
Name Time Method Significant reduction of glycemic index of test food Immediately after product administration (single use) Significant reduction in postprandial glycemia Immediately after product administration (single use) Significant reduction in postprandial insulinemia Immediately after product administration (single use)
Trial Locations
- Locations (1)
Institut des Nutraceutiques et des Aliments Fonctionnels (INAF)
🇨🇦Quebec, Canada
Institut des Nutraceutiques et des Aliments Fonctionnels (INAF)🇨🇦Quebec, Canada